Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00226395 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Oxymorphone Immediate Release in Post-surgical Acute Pain
A Phase 3 study of Acute Pain, sponsored by Endo Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 320
- Enrollment target
- 20
- Study locations
NCT00226395 is a Phase 3 study of Acute Pain that has completed, run by Endo Pharmaceuticals. The registered enrollment target is 320 participants, above the 262-participant average among 50 other Acute Pain trials with a reported enrollment target (22% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT00226395, a Phase 3 study of Acute Pain, has completed, sponsored by Endo Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 320 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the analgesic efficacy and safety of two doses of oxymorphone immediate release (IR) compared to placebo and oxycodone in post-surgical pain.
Conditions Studied
Interventions
- DRUG Oxymorphone immediate release
Study Locations (20)
Alabama
- Brookwood Medical Center - Birmingham
- The Medical Center, Dept. Clinical research - Birmingham
- Montgomery Women's Health Associates - Montgomery
Arizona
- Arrowhead Community Hospital - Phoenix
- John C Lincoln Hospital - Phoenix
- Paradise Valley Hospital - Phoenix
California
- Glendale Adventist Medical Center - Glendale
- Saddleback Memorial Medical Center - Laguna Hills
- Huntington Memorial Hospital - Pasadena
North Carolina
- Duke University Medical Center - Durham
- Forsyth Medical Center - Winston-Salem
- Medical Park Hospital - Winston-Salem
Florida
- Palm West Hospital - Palm Springs
- Sacred Heart Hospital - Pensacola
Pennsylvania
- Univ. Pittsburgh Hospital - Pittsburgh
- Univ. Pittsburgh Medical center - Pittsburgh
Texas
- Memorial Hermann Memorial City Hospital - Houston
- The Methodist Hospital - Houston
Utah
- Cottonwood Hospital - Salt Lake City
- LDS Hospital - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2004-09 |
| Est. Completion | 2005-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00226395
The ClinicalTrials.gov registry entry for NCT00226395 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 320 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 262-participant average among 50 other Acute Pain trials with a reported enrollment target (22% higher). The listed sponsor is Endo Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Pain appearing as the primary indexed condition, and to 1 intervention - of which Oxymorphone immediate release is the first listed.
NCT00226395 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Alabama, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT00226395 about?
NCT00226395 is a clinical study titled "Efficacy and Safety of Oxymorphone Immediate Release in Post-surgical Acute Pain". The purpose of this study is to evaluate the analgesic efficacy and safety of two doses of oxymorphone immediate release (IR) compared to placebo and oxycodone in post-surgical pain.
What is the current status of trial NCT00226395?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 320 participants. The study started on 2004-09. Estimated completion is 2005-08.
What conditions does trial NCT00226395 study?
This clinical trial studies the following conditions: Acute Pain.
What interventions are being tested in trial NCT00226395?
The interventions under investigation include: Oxymorphone immediate release (DRUG).
Who is sponsoring clinical trial NCT00226395?
This trial is sponsored by Endo Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00226395 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy of XP20B Following Bunionectomy Surgery
COMPLETED · Phase 3
-
Efficacy of Lidocaine Patch in Acute Musculoskeletal Pain in the Emergency Department
COMPLETED · Phase 3
-
Diclofenac Patch for the Treatment of Acute Pain Due to Mild to Moderate Wrist Sprain, Strain or Contusion
COMPLETED · Phase 3
-
Erector Spinae Block Versus Surgeon Infiltration in VATS Procedures
COMPLETED · Phase 3
-
A Study of Cebranopadol for the Treatment of Acute Pain After Bunionectomy
COMPLETED · Phase 3
-
Clinical Trial Comparing Two Protocols Using Intravenous (IV) Hydromorphone
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.